ReviewCancer biotherapy & radiopharmaceuticals2018
Radioimmunotherapy as a Novel Approach in HIV, Bacterial, and Fungal Infectious Diseases.
Review in Cancer biotherapy & radiopharmaceuticals, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- New approaches for cryptococcosis treatment and prevention-a systematic review.Journal of thoracic disease · 2026Review
- Synergistic Effects of IMP-1700, Ciprofloxacin, and X-Ray Radiation in Bacteria and Mammalian Cell Lines: Implications for Use in Antimicrobial-Resistant Bacteria.MicrobiologyOpen · 2026Article
- The Advancement of Targeted Alpha Therapy and the Role of Click Chemistry Therein.Molecules (Basel, Switzerland) · 2025Review
- Aspects and prospects of preclinical theranostic radiopharmaceutical development.Theranostics · 2024Review
- Evaluating the Targeting of aInternational journal of molecular sciences · 2023Article
- Development of radiopharmaceuticals for targeted alpha therapy: Where do we stand?Frontiers in medicine · 2022Review
- Radionuclide Imaging of Fungal Infections and Correlation with the Host Defense Response.Journal of fungi (Basel, Switzerland) · 2021Review
- Nuclear Medicine in Times of COVID-19: How Radiopharmaceuticals Could Help to Fight the Current and Future Pandemics.Pharmaceutics · 2020Review
- Photoimmunotherapy Using Cationic and Anionic Photosensitizer-Antibody Conjugates against HIV Env-Expressing Cells.International journal of molecular sciences · 2020Article
- Safety Evaluation of an Alpha-Emitter Bismuth-213 Labeled Antibody to (1→3)-β-Glucan in Healthy Dogs as a Prelude for a Trial in Companion Dogs with Invasive Fungal Infections.Molecules (Basel, Switzerland) · 2020Article
- Treating infections with ionizing radiation: a historical perspective and emerging techniques.Antimicrobial resistance and infection control · 2020Review
- Atomic Nanogenerators in Targeted Alpha Therapies: Curie's Legacy in Modern Cancer Management.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Three Discipline Collaborative Radiation Therapy (3DCRT) special debate: In the future, at least 20% of NIH funding for radiotherapy research should be allocated to non-oncologic applications.Journal of applied clinical medical physics · 2020Article
- Radioimmunotherapy of methicillin-resistant Staphylococcus aureus in planktonic state and biofilms.PloS one · 2020Article
- Radioimmunotherapy of Blastomycosis in a Mouse Model With a (1→3)-β-Glucans Targeting Antibody.Frontiers in microbiology · 2020Article
- Future Vistas in Alpha Therapy of Infectious Diseases.Journal of medical imaging and radiation sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the past several decades, many antimicrobial agents have been used in treating different fungal, bacterial, and viral infections. However, these agents have faced challenges such as pronounced side-effect profiles and pathogen resistance. In addition, a cure for many chronic infections such as human immunodeficiency virus (HIV) has not been achieved, and the incidence of opportunistic infections in immunocompromised patients has increased significantly in the past decades. Therefore, an alternative strategy for combating these infections is needed. Radioimmunotherapy (RIT) has been proposed to be a valuable tool in the management of such infections. The side-effects associated with RIT are minimal as the targeted antigens are only expressed on microbial or infected cells. RIT demonstrated impressive potency in eradicating pathogens in animal models and patient samples. Cryptococcus neoformans, HIV, and Bacillus anthracis are few examples of infections for which RIT has been an effective treatment using radionuclides such as bismuth-213 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.